Aethlon Medical Inc 最近的每股收益为 $-2.45,未达预期 $-2.46 的预期。
Aethlon Medical Inc AEMD 上一季度的收入表现如何?
Aethlon Medical Inc 上一季度的收入为 $-2.45
Aethlon Medical Inc 的收入预期是多少?
根据 3 位华尔街分析师的预测,Aethlon Medical Inc 的收入预期范围从 $0.0 到 $0.0
Aethlon Medical Inc 的盈利质量评分是多少?
Aethlon Medical Inc 的盈利质量评分为 A-/58.25362。该评分基于盈利能力、增长、现金生成与资本分配以及杠杆四个维度。
Aethlon Medical Inc 何时发布财报?
Aethlon Medical Inc 的下一份财报预计在 2026-05-13 发布
Aethlon Medical Inc 的预期收益是多少?
根据华尔街分析师的预测,Aethlon Medical Inc 的预期收益为 $0.0
Aethlon Medical Inc 是否超出收益预期?
Aethlon Medical Inc 最近的收益为 $0.0,未达预期 预期。
关键数据
前收盘价
$2.19
开盘价
$2.18
当日区间
$2.18 - $2.29
52周范围
$1.36 - $35.2
交易量
43.7K
平均成交量
51.9K
股息收益率
--
每股收益(TTM)
-49.89
市值
$3.5M
什么是 AEMD?
Aethlon Medical, Inc. is a medical technology company which focuses on developing products to diagnose and treat life and organ threatening diseases. The company is headquartered in San Diego, California and currently employs 9 full-time employees. The firm is focused on advancing the Hemopurifier (HP), a clinical-stage immunotherapeutic device intended for applications in cancer, life-threatening viral infections, and organ transplantation and other areas of significant unmet needs. In pre-clinical studies, the Hemopurifier has exhibited the capacity to remove harmful extracellular vesicles (EVs) and enveloped viruses from biological fluids, utilizing its proprietary lectin-based mechanism. These extracellular vesicles have been implicated in disease processes such as immune suppression and metastasis in cancer as well as in the progression of severe life-threatening infectious diseases. The United States Food and Drug Administration (FDA) has designated the Hemopurifier as a Breakthrough Device for the treatment of individuals with advanced or metastatic cancer who are unresponsive to or intolerant of standard of care therapy.